Vimta Labs schedules October 30 Q2 FY27 board meeting

Vimta Labs Limited will hold a board meeting on October 30, 2026, to consider unaudited results for the quarter and half-year ended September 30, 2026. The filing matters because Vimta Labs reported ₹418.8 crore in revenue and ₹79.66 crore in net profit, while its June 2026 quarter generated ₹109.07 crore in total revenue.

When will Vimta Labs announce its Q2 FY27 results?

Vimta Labs will consider and approve its unaudited Q2 FY27 and first-half FY27 financial results at a board meeting scheduled for October 30, 2026. The company informed BSE of the meeting on October 24 under the listing regulations.

The results will cover the three months and six months ended September 30, 2026. As of the meeting intimation, Vimta Labs had not disclosed the September-quarter revenue, profit, margin, or any revised business guidance. Investors will therefore await the board-approved financial statements for the confirmed Q2 figures.

The company has also said that the trading window has been closed from October 1. Such closures are a standard compliance measure ahead of the publication of unpublished price-sensitive financial information.

What is planned for the Vimta Labs investor call?

Vimta Labs has scheduled an analyst and investor conference call for 2:30 PM IST on October 30, 2026, following the release of its Q2 FY27 financial results. The company said call and dial-in details would be made available to participants and posted on its website.

The conference call is intended to discuss the quarter and the half-year financial performance with shareholders, analysts, and other market participants. The intimation describes a routine earnings discussion and does not announce any material change in financial guidance or operations.

The timing will allow the management to address questions after the unaudited results are released. Any comments on demand conditions, margins, capacity spending, or service-line performance will need to be assessed against the financial disclosures issued by the company.

How did Vimta Labs perform before the Q2 FY27 announcement?

Vimta Labs reported total revenue of ₹109.07 crore for the quarter ended June 2026, compared with ₹97.56 crore in the quarter ended June 2025. Operating profit for the June 2026 quarter was ₹37.31 crore, versus ₹33.69 crore a year earlier.

Operating profit margin was 34% in the June 2026 quarter, compared with 35% in the June 2025 quarter. Depreciation increased to ₹12.55 crore from ₹9.86 crore over the same period, while interest expense was ₹0.24 crore compared with ₹0.32 crore.

For FY26, the company reported revenue of ₹418.8 crore and net profit of ₹79.66 crore. These figures provide the broader base against which investors may review the first-half FY27 result when it is released.

What is the background to Vimta Labs' recent operating performance?

Vimta Labs previously said it recorded its highest-ever quarterly sales revenue in Q2 FY26, reporting sales revenue of ₹104.5 crore. The company attributed that performance to its pharma and food testing services, and reported total income of ₹104.5 crore, EBITDA of ₹36.9 crore, and profit after tax of ₹19.9 crore for that quarter.

The company also reported that Q2 FY26 sales revenue rose 22.3% year on year, while EBITDA increased 20.6% and profit after tax rose 17.1%. The stated margin and earnings data indicate that operating performance was supported by the testing-services business during that period.

In 2025, Vimta Labs divested its diagnostics business to focus on its core operations. This portfolio change is relevant when comparing financial periods, as the company has positioned its operating model around its core testing and research-related services.

Why does the Q2 FY27 result matter to Vimta Labs investors?

The Q2 FY27 release will show whether Vimta Labs has maintained the revenue scale achieved in the June 2026 quarter and how operating profitability has moved after the 34% operating margin reported in that period. It will also provide the first disclosed half-year view of FY27 performance.

Investors may compare the upcoming numbers with the June 2026 quarter, when revenue was ₹109.07 crore and operating profit was ₹37.31 crore. They may also track depreciation, which had risen year on year, because it affects profit after operating expenses.

The result is relevant to the broader contract research, testing, and laboratory-services industry because Vimta Labs has cited pharma and food testing as contributors to its earlier record quarterly revenue. However, the company has not yet released Q2 FY27 service-wise data or guidance, so the extent of any change in individual business lines remains undisclosed.

Conclusion

Vimta Labs' October 30 board meeting and post-results conference call are the next formal events for investors seeking the company's Q2 FY27 and first-half FY27 financial update. The company enters the announcement after reporting FY26 revenue of ₹418.8 crore and net profit of ₹79.66 crore, with June-quarter revenue of ₹109.07 crore.

The immediate item to watch is the unaudited result for the quarter ended September 30, 2026, followed by management comments during the 2:30 PM IST investor call. The filing does not provide Q2 financial figures or revised guidance ahead of the scheduled meeting.